 |
2023 News Releases
Nov. 6, 2023 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
Nov. 2, 2023 - Puma Biotechnology Reports Third Quarter 2023 Financial Results
Read
Oct. 19, 2023 - Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2023 Financial Results
Read
Oct. 14, 2023 - Puma Biotechnology Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting
Read
Oct. 4, 2023 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
Sept. 21, 2023 - Puma Biotechnology Receives FDA Orphan Drug Designation for Alisertib for the Treatment of Small Cell Lung Cancer
Read
Aug. 31, 2023 - Puma Biotechnology to Present at the H.C. Wainwright 25 th Annual Global Investment Conference
Read
Aug. 8, 2023 - Puma Biotechnology Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer
Read
Aug. 3, 2023 - Puma Biotechnology Reports Second Quarter Financial Results
Read
July 20, 2023 - Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2023 Financial Results
Read
June 6, 2023 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
June 4, 2023 - Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting
Read
May 5, 2023 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
May 4, 2023 - Puma Biotechnology Reports First Quarter Financial Results
Read
Apr. 20, 2023 - Puma Biotechnology to Host Conference Call to Discuss First Quarter 2023 Financial Results
Read
Apr. 11, 2023 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
Mar. 14, 2023 - Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology
Read
Mar. 3, 2023 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
Mar. 2, 2023 - Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
Read
Feb. 28, 2023 - Puma Biotechnology to Participate in a Panel Discussion at Cowen’s 43rd Annual Health Care Conference
Read
Feb. 16, 2023 - Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results
Read
Feb. 1, 2023 - Puma Biotechnology’s NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Breast Cancer with a HER2 Mutation
Read
Jan. 12, 2023 - Puma Biotechnology to Present at B. Riley Securities’ 3rd Annual Oncology Conference
Read
Jan. 11, 2023 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
Jan. 9, 2023 - Puma Biotechnology Releases Updated Corporate Presentation
Read
|
Puma Biotechnology, Inc.
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax
|
